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Abstract
This paper introduces a unified framework of counterfactual estimation for time-series
cross-sectional data, which estimates the average treatment effect on the treated by dir-
ectly imputing treated counterfactuals. Examples include the fixed effects counterfac-
tual estimator, interactive fixed effects counterfactual estimator, and matrix completion
estimator. These estimators provide more reliable causal estimates than conventional
twoway fixed effects models when treatment effects are heterogeneous or unobserved
time-varying confounders exist. Under this framework, we propose a new dynamic
treatment effects plot, as well as several diagnostic tests, to help researchers gauge the
validity of the identifying assumptions. We illustrate these methods with two political
economy examples and develop an open-source package, fect, in both R and Stata to
facilitate implementation.
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The linear twoway fixed effects (FE) model is one of the most commonly used statistical
routines in the social sciences to establish causal relationships using observational time-
series cross-sectional (TSCS) data, or long panel data. Such models are a popular choice
because they can potentially control for a large set of unobserved unit- and time-invariant
confounders. However, recent research points to several important drawbacks of FE models
(Blackwell and Glynn 2018; Imai and Kim 2019). First, the strict exogeneity assumption they
rely on is often unrealistic—it not only requires the absence of time-varying confounders, but
also rules out the possibility that past outcomes directly affect current treatment assignment
(no feedback). It is well known that violations of strict exogeneity lead to biases in the causal
estimates, yet methods for relaxing it or diagnosing its failure remain limited.
Second, FE models involve rigid functional form assumptions. If we focus on the cases
of dichotomous treatments, FE models often assume their effects to be constant (constant
treatment effect) and they affect the contemporaneous outcome only, not future outcomes
(no carryover effects). Violation of the former will likely result in biased estimates even
when strict exogeneity is satisfied, a problem receiving much attention in the literature
recently. For example, Goodman-Bacon (2021) shows that, in a staggered adoption setting
where a treatment never switches back once it is on, twoway FE estimates are weighted
averages of individualistic treatment effects, or treatment effects on each cell under the
treatment condition. Because the weights can sometimes be negative, twoway FE estimates
may not even be convex combinations of the individualistic effects. de Chaisemartin and
d’Haultfoeuille (2020) extend the analysis to TSCS data with a general treatment structure
in which the treatment may switch on and off, and find a similar negative weighting result.
Several papers aim to address this issue. For example, Strezhnev (2018) and Callaway and
Sant’Anna (2020) suggest that under staggered adoption, researchers can instead estimate
the average treatment effects for units that adopt the treatment at the same time, which
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they call the cohort average treatment effect; de Chaisemartin and d’Haultfoeuille (2020)
propose to use observations only one period before or after the treatment’s onset, which leads
to an estimator they call DiDM (M for “multiple”). However, these approaches either have
limited applicability by requiring a staggered adoption design or are statistically inefficient
due to dropping many observations. Moreover, so far researchers have paid little attention
to the no carryover effects assumption, though it may be testable by data.
In this paper, we introduce a simple framework that ameliorates these problems. We
focus on TSCS data with dichotomous treatments, but they are allowed to switch back and
forth (we call it a general panel treatment structure). Estimators under this framework take
observations under the treatment condition as missing, use data under the control condi-
tion only to build models, and impute counterfactuals of treated observations based on the
estimated models. We call them counterfactual estimators. This framework has several be-
nefits. First, by not using the treated observations at the model-building stage and imposing
uniform weights on individualistic treatment effects on treated observations, it avoids the
aforementioned negative weights problem and corrects biases induced by treatment effect
heterogeneity. Second, it accommodates a variety of models, some of which can potentially
relax the conventional strict exogeneity assumption. Third, our approach also makes dia-
gnostics and visualization much easier than with traditional twoway FE models.1
As examples, we survey three methods under this framework that have recently emerged
in the literature, including (1) the fixed effects counterfactual (FEct) estimator, of which
difference-in-differences (DiD) is a special case; (2) the interactive fixed effects counterfactual
(IFEct) estimator (Gobillon and Magnac 2016; Xu 2017); and (3) the matrix completion
(MC) estimator (Athey et al. 2021; Kidziński and Hastie 2018). Both the IFEct and MC
estimators use a latent factor approach to adjust for potential time-varying confounders.
Mathematically, these estimators are designed to construct a lower-rank approximation of
1It is worth noting that traditional twoway FE models can also be seen as counterfactual
estimators with an additional constant treatment effects assumption.
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the outcome data matrix using information of untreated observations but differ in their
ways of regularizing latent factors. Previous work and results in this paper suggest that
they can provide more reliable causal estimates than conventional methods if potential time-
varying confounders can be expressed as interactions between time-varying common shocks
and unit-specific intercepts.
Moreover, this paper aims to provide researchers with a set of diagnostic tools when
making causal claims using TSCS data. A popular practice among researchers to evaluate the
validity of the identifying assumption is to draw a plot of the so-called “dynamic treatment
effects,” which are coefficients of a series of interactions between a dummy variable indicating
the treatment group—units that are exposed to the treatment for at least one period during
the observed time window—and a set of time dummies indicating the time period relative to
the onset of the treatment using a twoway FE model. If these coefficients exhibit a monotonic
trend leading toward the onset of the treatment, or a “pretrend,” the assumption is deemed
problematic. However, this method relies on parametric assumptions and the statistical
tests derived from it are informal, often underpowered, or even misleading (Roth 2020;
Sun and Abraham 2020). Taking advantage of the counterfactual estimation framework, we
improve the practice of estimating and plotting the dynamic treatment effects, or the average
treatment effects on the treated (ATT) over different periods, without assuming treatment
effect homogeneity of any kind.
In addition to visual inspections, we propose a set of statistical tests to help researchers
evaluate the validity of the identifying assumptions. The core of these tests is based on a
panel placebo test, in which we hide a few periods of observations right before the onset of
the treatment for the treated units and use a model trained using the rest of the untreated
observations to predict the untreated outcomes of those held-out periods. If the identifying
assumptions are valid, the average differences between the observed and predicted outcomes
in those periods should be close to zero. If, on the contrary, these differences are significantly
different from zero, we obtain a piece of evidence that either the functional form assumption
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or strict exogeneity is likely invalid.
We then use this basic idea to construct two additional tests, a test for no pretrend
and a test for no carryover effects. With the former, instead of hiding a few periods right
before the treatment begins, we use a leave-one-out (LOO) approach to consecutively hide
one pretreatment period (relative to the timing of the treatment) and repeatedly conduct a
placebo test on observations in that period. By doing so, we have a more holistic view of
whether the identifying assumptions likely hold—in the online Supplementary Information
(SI), we provide an empirical example that passes the placebo test but fails the pretrend
test. The test for no carryover effects, on the other hand, is the mirror opposite of the
placebo test in that it hides a few periods right after the treatment ends. If carryover effects
do not exist, the average differences between the observed and predicted outcomes in those
periods should be close to zero. This test is infeasible for the staggered adoption treatment
structure, in which the treatment never switches back. However, under staggered adoption,
potential carryover effects may not be concerns for researchers who care about the overall
cumulative effects of the treatment over an extended period of time.
For all three tests, we use both a conventional difference-in-means (DiM) approach, which
tests against the null of no difference, and an equivalence approach, which flips the null and
tests against a prespecified difference. Consistent with the literature on equivalence tests
in cross-sectional settings (Hartman and Hidalgo 2018; Hartman 2020), we show that the
equivalence approach has advantages over the DiM approach when limited power is a concern.
This is because as researchers collect more data, under valid identifying assumptions, it
should be easier for them to declare equivalence by rejecting null in an equivalence test, not
harder. We recommend that researchers use these tests together to obtain a full picture of
the likelihood of valid research designs.
This paper makes two main contributions to the literature. First, it introduces a coun-
terfactual estimation framework to TSCS analysis that covers a variety of novel estimators.
This new estimation approach fixes the weighting issue of twoway FE models that causes
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concern for many researchers, and the new estimators introduced here can potentially con-
trol for decomposable time-varying confounders in a general panel data setting. Our second
contribution is to develop a set of visualization and diagnostic tools to assist researchers in
gauging the validity of identifying assumptions and choosing the most suitable model for
their applications.
This paper builds on earlier work on counterfactual estimation (or imputation methods)
for causal inference. Heckman, Ichimura and Todd (1997, 1998) first noted that, to identify
the ATT, one only needs to impute counterfactuals for observations in the treatment group.
This perspective has motivated a series of studies that try to predict the counterfactual in
cross-sectional studies using various methods, such as regression (Lin 2013), the Oaxaca-
Blinder estimator (Kline 2011), and machine learning algorithms (Künzel et al. 2019). The
synthetic control method (SCM) first adopts the counterfactual approach in a panel setting
(Abadie, Diamond and Hainmueller 2010), but it is limited to comparative case studies, a
highly specialized user case. We fill the gap of systematically introducing it to analyzing
TSCS data. In addition to us, Borusyak, Jaravel and Spiess (2020) and Gardner (2021) have
applied the idea to DiD analysis.
Our approach also contributes to an emerging literature on causal inference with TSCS
data and has advantages over existing methods under some circumstances. Compared
with existing factor-augmented methods (e.g., Gobillon and Magnac 2016; Xu 2017), which
are also counterfactual estimators, our framework can accommodate more complex TSCS
designs, such as treatment reversal. Compared with TSCS methods based on matching and
reweighting under strict exogeneity (e.g., Abadie 2005; Imai and Kim 2019; Strezhnev 2018;
Callaway and Sant’Anna 2020; de Chaisemartin and d’Haultfoeuille 2020), our imputation
approach can accommodate more complex data structure and incorporate covariates more
conveniently, and is often more efficient. Our method can also serve as a building block for




This section introduces the framework, the estimation strategy, and three novel estimators
as examples.
2.1. A Simple, Unified Framework
Setup. Though our approach can accommodate both balanced and imbalanced panels, we
consider a balanced panel with N units and T periods for notational convenience. Denote
Dit the treatment status. Denote Yit(1) and Yit(0) the potential outcomes of unit i in period t
when Dit = 1 and Dit = 0, respectively. Denote Xit a vector of the exogenous covariates, Uit
the unobservable attributes, and εit the idiosyncratic error term. Without loss of generality,
we can define δit = Yit(1) − Yit(0) for unit i in period t. We assume the following class of
outcome models for the untreated potential outcome:
Assumption 1 (Functional form) Yit(0) = f(Xit) + h(Uit) + εit, in which f(·) and h(·) are
known, parametric functions.
It is easy to see that the classic two-group two-period DiD approach assumes a model that
is a special case in Assumption 1:
Yit(0) = Uit + εit = αi + ξt + εit, t = 1, 2
in which αi and ξt are unit and period fixed effects. Note that Assumption 1 requires
additive separability of the four right-hand side terms. This class of models is scale dependent
(Athey and Imbens 2006), i.e., transforming the outcome from levels to logarithms may
render the identification assumptions discussed below invalid. Here, we highlight the fact
that FE models’ ability to control for unobserved confounders rests on the functional form
assumption.
Assumption 1 also rules out cross-sectional spillover of treatment effects or carryover
effects to future periods with a general panel treatment structure. In a staggered adoption
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design, however, carryover effects are allowed because we can interpret δit as a combination
of instant effect of the current treatment and cumulative carryover effects of past treatments
on a treated unit relative to its potential outcome history under the never-treated condition
(see a graphic illustration in SI).
Estimands. The primary causal quantity of interest is the average treatment effect on the
treated units, whose treatment status has changed at least once during the observed time
window (referred to as T ), i.e.,
ATT = E[δit|Dit = 1,∀i ∈ T ,∀t], T := {i | ∃t, t′ s.t. Dit = 0, Dit′ = 1}
in which δit = Yit(1) − Yit(0) by definition. For units that have never been exposed to
the treatment condition, it is difficult to compute their treated potential outcomes without
strong structural assumptions. Similarly, it is difficult to estimate causal effects on units
that are always treated, and we drop them from the sample at the preprocessing stage. In
empirical work, researchers may be also interested in the average treatment effect on the
treated at sth (s > 0) periods since the treatment’s onset:
ATTs = E[δit|Di,t−s = 0, Di,t−s+1 = Di,t−s+2 = · · · = Dit = 1︸ ︷︷ ︸
s periods
,∀i ∈ T ], s > 0.
For the purpose of the diagnostic tests we will introduce later, we define ATTs = 0,∀s ≤ 0.
Assumption 2 (Strict exogeneity) eit ⊥⊥ {Djs,Xjs,Ujs}, for all i, j ∈ {1, 2, . . . , N} and
s, t ∈ {1, 2, . . . , T}.
Together with Assumption 1, Assumption 2 implies within-unit quasi-randomization condi-
tional on X and U, that is, Yis(0) ⊥⊥ Dit |Xi,1...T ,Ui,1...T , ∀i, s, t, in which Xi,1...T and Ui,1...T
are the time series of X and U, respectively. When h(Uit) = αi+ξt (as in DiD), Assumption
2 implies the parallel trends assumption, i.e.,
E[Y (0)it|Xit]− E[Y (0)is|Xis] = E[Y (0)jt|Xjt]− E[Y (0)js|Xjs], ∀i, j,∀t, s,
which states that, by expectation, the untreated potential outcome of all units follow parallel
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paths. When Uit is of a more general form, Assumption 2 implies
E[Y (0)it|Xit,Uit]−E[Y (0)is|Xis,Uis] = E[Y (0)jt|Xjt,Ujt]−E[Y (0)js|Xjs,Ujs], ∀i, j,∀t, s
which states that conditional on the observed exogenous covariates and unobserved attributes
(if we can extract them), the average changes in untreated potential outcome from period s
to period t is the same between unit i and unit j. This leads to the third assumption.
Assumption 3 (Low-dimensional decomposition) There exists a low-dimensional decompos-
ition of h(Uit): h(Uit) = Lit, and rank(LN×T )  min{N, T}. For example, L = ΛF, in
which Λ is a (N × r) matrix of factor loadings and F is a (r × T ) matrix of factors and
r  min{N, T}.
Assumption 3 allows us to condition on Uit. To give a concrete example, if Uit = ft · λi is
one dimensional, we can understand it as the impact of a common time trend ft having a
heterogeneous impact on each unit, whose heterogeneity is captured by λi. Moreover, when
ft is constant, Uit reduces to a set of unit fixed effects; when λi is constant, it reduces to time
fixed effects. Hence, additive fixed effects in DiD models obviously satisfy this assumption.
When unobserved confounders Uit exist, treatment assignment is dependent on observed
untreated outcomes, thus, we are operating under a special case of missing not at random
(Rubin 1976). Assumption 3 allows us to break this dependency by controlling for Uit
approximated by data and can be understood as a feasibility assumption.
In Figure 1, we illustrate what the identification assumptions entail, using a directed
acyclic graph (DAG). It shows that Assumptions 1-2 rule out carryover effects (e.g., no
arrow from Dt to Yt+1), feedback (e.g., no arrow from Yt−1 to Dt), and lagged dependent
variables (no arrow from Yt−1 to Yt); it also shows that the treatment effects of Dit on Yit
are separable from the influences of Uit and Xit. This setup nests many existing models for
TSCS data analyses, including twoway FE and IFE models, although these models usually
assume constant treatment effect, i.e, δit = δ. If these assumptions are unsatisfied, research
may turn to methods under sequential ignorability. See more discussion in Blackwell and
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Figure 1. A DAG Illustration
Yt−1 Yt Yt+1
Dt+1DtDt−1
εt−1 εt εt+1Xt−1 Xt Xt+1
Ut−1 Ut Ut+1
Note: Unit indices are dropped for simplicity.
Glynn (2018) and Imai and Kim (2019) on the potential tradeoffs.
Estimation strategy. We define the observations under control and treatment conditions
as O = {(i, t)|Dit = 0} and M = {(i, t)|i ∈ T , Dit = 1}, respectively, in which O stands for
“observed” and M stands for “missing.” Although the outcome model researchers choose
to employ may vary, estimation proceeds in a similar fashion with the following steps:
Step 1. On the subset of untreated observations (O), fit a model of the response surface
Yit, obtaining f̂ and ĥ. This step relies on the functional form assumptions on f(Xit) and
h(U), as well as a lower-rank representation of U.
Step 2. Predict the counterfactual outcome Yit(0) for each treated observation using f̂ ,
ĥ(U), i.e., Ŷit(0) = f̂(Xit) + ĥ(Uit), for all (i, t) ∈M.
Step 3. Estimate the individualistic treatment effects δit using δ̂it = Yit − Ŷit(0) for each
treated observation (i, t) ∈ M. Note that δit is not individually identified because of idio-
syncratic errors.
Step 4. Take averages of δ̂it to produce estimates for the quantities of interest. For example,
for the ATT, ÂTT = 1|M|
∑





(i,t)∈S δ̂it, in which S = {(i, t)|Di,t−s = 0, Di,t−s+1 = Di,t−s+2 = · · · = Dit = 1}.
|A| denotes the number of elements in set A.
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The above counterfactual approach addresses the negative weighting issue by assigning
uniform weights to the treated observations after their counterfactuals are imputed. Com-
pared with existing approaches, such as DiDM (de Chaisemartin and d’Haultfoeuille 2020),
this approach is more efficient because it uses all available data without imposing stronger
functional form assumptions. It also allows researchers to communicate estimation results
and conduct diagnostic tests in a transparent way.
2.2. Three Novel Estimators as Examples
In this subsection, we review three estimators as examples of this framework. They are
conceptually similar because they follow the same identification strategy laid out above.
a) The fixed effects counterfactual estimator. We start by introducing the twoway
fixed effects counterfactual estimator, in which Yit, (i, t) ∈ O is fitted by a twoway FE model:
Yit(0) = X
′
itβ + αi + ξt + εit, for all (i, t).
In other words, we assume f(Xit) = X
′







ξt, is imposed to achieve identification (a grand intercept
is unnecessary under this constraint).
It is easy to see that in a classic DiD setup with two groups, two periods and no covariates,
the FEct estimator is the DiD estimator. How does FEct address the weighting issue with a
general panel treatment structure? Arkhangelsky and Imbens (2021) show that with additive
unit and time fixed effects, any estimator that aims at identifying a convex combination of
δit can be written as a weighted average of Yit, where the weights {wit}1≤i≤N,1≤t≤T must





t=1witDit = 1; (2)
∑T
t=1 wit = 0 for
any i; (3)
∑N
t=1 wit = 0 for any t; and (4) witDit ≥ 0 for any (i, t). Weights from both a
twoway FE model and FEct meet conditions (1)-(3). However, the former violates the last
condition while latter does not; in fact, FEct imposes wit:Dit=1 =
1
|M| , which guarantees the
identification of the causal quantities, such as ATT and ATTs. We can therefore rewrite FEct
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as as a weighting estimator; that is, each treated observation is matched with its predicted
counterfactual Ŷit(0) = W
(it)′YO, which is the weighted sum of all untreated observations.
Comparison within each matched pair removes the biases caused by improper weighting that
plague conventional FE models. We provide the proofs for both results in SI.
Proposition 1 (Unbiasedness and consistency of FEct) Under Assumptions 1-3, as well
as some regularity conditions,
E[ÂTT s] = ATTs; E[ÂTT ] = ATT ;
ÂTT s − ATTs
p→ 0; and ÂTT − ATT p→ 0 as N →∞.
Proposition 2 (FEct as a weighting estimator) Under Assumptions 1-3 and when there












. . . ,W
(it)
js , . . .
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b) The interactive fixed effects counterfactual (IFEct) estimator. FEct estimates
will be biased when unobserved time-varying confounders exist. A couple of authors have
proposed using factor-augmented models to relax the strict exogeneity assumption (Bai 2009;
Gobillon and Magnac 2016; Xu 2017; Bai and Ng 2021). IFEct models the response surface
of untreated potential outcomes using a factor-augmented model:
Yit(0) = X
′
itβ + αi + ξt + λ
′
ift + εit, for all (i, t).
In other words, f(Xit) = X
′
itβ and h(Uit) = αi + ξt + λ
′
ift. When the model is correctly
specified, IFEct is consistent. We provide its algorithm, as well as the proof of the following
proposition, in SI.
Proposition 3 (Consistency of IFEct) Under Assumptions 1-3, as well as some regularity
conditions, ÂTT
p→ ATT as N, T →∞.
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c) The matrix completion estimator. Athey et al. (2021) introduce the MC method
from the computer science literature as a generalization of factor-augmented models. Similar
to FEct and IFEct, it treats a causal inference problem as a task of completing a (N × T )
matrix with missing entries, where missing occurs when Dit = 1. Mathematically, MC
assumes that the (N × T ) matrix of [h(Uit)]i=1,2,...,N,t=1,2,...,T can be approximated by a
lower-rank matrix L(N×T ), i.e.,
Y(0) = Xβ + L + ε,
in which Y is a (N × T ) matrix of untreated outcomes; X is a (N × T × k) array of
covariates; and ε represents a (N × T ) matrix of idiosyncratic errors. As with IFEct, L can
be expressed as the product of two r-dimension matrices: L = ΛF. Unlike IFEct, however,
the MC estimator does not explicitly estimate F and Λ; instead, it seeks to directly estimate
L by solving the following minimization problem:








in which O = {(i, t)|Dit = 0}, ‖L‖ is the chosen matrix norm of L, and λL is a tuning
parameter. Athey et al. (2021) propose an iterative algorithm to obtain L̂ and show that L̂
is an asymptotically unbiased estimator for L. We summarize the algorithm in SI.
Remark 1: The difference between IFEct and MC. The main difference between
IFEct and MC lies in the way they regularize the singular values when decomposing the
residual matrix. IFEct uses a “best subset” approach that selects the r biggest singular
values, in which r is a fixed number and r < min{N, T}, while MC imposes an L1 penalty
on all singular values with a tuning parameter λL. In the machine learning literature,
they are referred to as hard impute and soft impute, respectively. Figure 2 illustrates how
regularization works with IFEct—which selects two factors in this case—and MC. It also
shows that they are fundamentally similar ideas (Athey et al. 2021).
Whether IFEct or MC performs better depends on context. In SI, we provide Monte
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Figure 2. Hard Impute (IFEct) vs. Soft Impute (MC)
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0 0 0 · · · 0

N×T
Hard Impute Soft Impute
Note: Adapted from Athey et al. (2021). |a|+ = max(a, 0)
Carlo evidence to show that when the factors are strong and sparse, IFEct outperforms MC;
otherwise, MC performs better. In practice, researchers may choose between the two models
based on how they behave under the diagnostic tests we introduce in the next section. When
r = 0 or when λL is bigger than the biggest singular value of the residual matrix, no factors
are included in the model; as a result, IFEct or MC reduces to FEct.
The IFEct estimator was first proposed by Gobillon and Magnac (2016) in a DiD setting
where the treatment takes place at the same time for a subset of units. It is also closely related
to the generalized synthetic control method (Xu 2017), in which factors are estimated using
the control group data only. In this paper, we accommodate with panel treatment structure,
which allows treatment reversal. In other words, the generalized synthetic control method
can be seen as a special case of IFEct when the treatment does not switch back.
Remark 2: Choosing the tuning parameters. In order to choose r for IFEct, we repeat
Step 2 on a training set of untreated observations until β̂ converges. The optimal r is then
chosen based on a prespecified model performance metric, such as mean squared prediction
error, using a k-fold cross-validation scheme. To preserve temporal correlations in the data,
the test set consists of a number of triplets (three consecutive untreated observations of
the same unit) from the treatment group. Similarly, for the MC estimator, we use k-fold
cross-validation to select the λL. The test set is constructed in the same way as in IFEct.
Remark 3: Inferential methods. We rely on nonparametric block bootstrap and jackknife—
both clustered at the unit level—to obtain uncertainty estimates for the treatment effect
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estimates. Our simulation results (reported in SI) suggest that both inferential methods
work well with reasonable sample sizes (e.g. T = 20, N = 100). In practice, we recommend
users use jackknife when the number of treated units is small.
3. Diagnostics
In this section, we introduce a set of diagnostic tools to assist researchers probing the validity
of the identifying assumptions. These assumptions should be considered collectively because
strict exogeneity (Assumption 2) hinges on a correct functional form (Assumption 1) and
bias removal is only possible when the feasibility condition (Assumption 3) is met. We first
introduce a plot for dynamic treatment effects based on counterfactual estimators. We then
propose several statistical tests for the implications of the identifying assumptions, including
a placebo test, a test for no pretrend, and a test for no carryover effects. The latter two can
be seen as as extension of the placebo test.
3.1. A Plot for Dynamic Treatment Effects
In applied research with TSCS data, researchers often plot the so-called “dynamic treatment
effects,” which are coefficients of the interaction terms between the treatment indicator and a
set of dummy variables indicating numbers of periods relative to the onset of the treatment
(lags and leads)—for example, s = −4,−3, · · · , 0, 1, · · · , 5 with s = 1 representing the
first period a unit receives the treatment—while controlling for unit and time fixed effects.
Researchers then gauge the plausibility of the strict exogeneity assumption by eyeballing
whether the coefficients in the pretreatment periods (when s ≤ 0) exhibit an upward or a
downward trend—often known as a “pretrend”—or are statistically significant from zero.
The magnitudes of the coefficients and corresponding p-values often depend on the baseline
category researchers choose, which varies from case to case.
We improve the dynamic treatment effect plot by taking advantage of the counterfactual
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estimators. Instead of plotting the interaction terms, we plot the averages of the differences
between Yit and Ŷit(0) for units in the treatment group (i ∈ T ), re-indexed based on the
time relative to the onset of the treatment. Specifically, we define δ̂it = Yit − Ŷit(0), for
all t, i ∈ T . When the identifying assumptions are correct, it is easy to see that average
pretreatment residuals will converge to zero, i.e., ÂTT s
p→ 0 for all s ≤ 0.2 Therefore, we
should expect pretreatment residual averages to be bouncing around zero, i.e., no strong
pretrend. Figure 3 illustrates how we takes averages of δ̂it based on the timing relative to
the next closest treatment.
Figure 3. Estimating the Dynamic Treatment Effects
−4 −3 −2 −1 0 1 2 3 4 5
−5 −4 −3 −2 −1 0 1 2 3 4
−6 −5 −4 −3 −2 −1 0 1 2 3
−7 −6 −5 −4 −3 −2 −1 0 1 2
−8 −7 −6 −5 −4 −3 −2 −1 0 1





Under Control Under Treatment
(a) Staggered Adoption
−2 −1 0 1 2 3
0 1 2 −1 0 1 2
−1 0 1 2 3 −3 −2 −1 0 1
−3 −2 −1 0 1 2 −1 0 1 2
−5 −4 −3 −2 −1 0 1 2 3 4





Under Control Under Treatment
(b) General Pattern
Note: The above figure shows the treatment status with two hypothetical examples: (a) staggered adoption
and (b) a general panel treatment structure. Numbers correspond to time relative to the onset of a treatment.
Several cells in (b) are not assigned numbers because left or right censorship of data makes their relative
positions to a treatment uncertain.
This method has two main advantages over the traditional approach. First, it relaxes
the constant treatment effect assumption. Even though the conventional dynamic treatment
effect plot allows the treatment effects to be different across time, it assumes a constant effect
for all treated units in a given time period (relative to the start of the next treatment).3
2With some abuse of the terminology, we call the residual averages ÂTT s when s ≤ 0.
3Sun and Abraham (2020) show that, under a staggered adoption design, if the dynamic
treatment effects differ across units, a spurious pretrend may arise even when the identifying
assumptions are valid.
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Second, because a unit’s untreated average has already been subtracted from δ̂it, it is no
longer necessary for researchers to choose a base category; to put it differently, the base
category is set at a unit’s untreated average after the time effects are partialed out.4 The
dynamic treatment effects plot is an intuitive “eyeball” test that can help researchers detect
data and modeling issues instantly.
We illustrate the plot using a simulated panel dataset of 200 units and 35 time periods
based on the following DGP with two latent factors, f1t and f2t:
Yit = δitDit + 5 + 1 ·Xit,1 + 3 ·Xit,2 + λi1 · f1t + λi2 · f2t + αi + ξt + εit,
where the heterogeneous individualistic treatment effectss are governed by δit = 0.4st + eit,
in which st represents the number of periods since the latest treatment’s onset and eit is i.i.d.
N(0, 0.16). This means the expected value of the treatment effect gradually increases as a
unit takes up the treatment. f1t is a linear trend plus white noise and f2t is an i.i.d. N(0, 1)
white noise. For each unit, the treatment may switch on and off. The probability of getting
the treatment is dependent on the treatment status in the previous period as well as the
interactive and additive fixed effects (see SI for details; this DGP satisfies Assumptions 1-3).
As a result, failure to adjust for these factors will lead to biases in the causal estimates.
Figure 4 shows the estimated dynamic treatment effects with 95% confidence intervals
based on block bootstraps of 1,000 times using the aforementioned counterfactual estimators.
They are benchmarked against the true ATTs, which we depict with red dashed lines. From
the left panel of Figure 4, we see that using the FEct estimator, (1) a strong pretrend leads
towards the onset of the treatment and multiple “ATT” estimates (residual averages) in the
pretreatment periods are significantly different from zero; and (2) there are sizable positive
biases in the ATT estimates in the posttreatment periods. We see a similar pattern in
4Intuitively, this approach will give more power to detecting a treatment effect because the
conditional mean is taken over observations in all pretreatment periods; whether this leads
to more strict or lenient criteria in diagnostic tests requires more research.
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Note: The above figure shows the dynamic treatment effects estimates from the simulated data using three
different estimators: FEct, IFEct, and MC. The bar plot at the bottom of each panel illustrates the number
of treated units at the given time period relative to the onset of the treatment (the number decreases as
time goes by because there are fewer and fewer units that are treated for a sustained period of time). The
red dashed lines indicate the true ATT.
the posttreatment periods in the right panel where the MC estimator is applied, though
with smaller biases. However, when using the IFEct estimator, the ATT estimates in both
pretreatment and posttreatment periods are very close to the truth. This is expected because
the DGP is generated by an IFE model with two latent factors and our cross-validation
scheme picks the correct number of factors. To help researchers gauge the effective sample
size, we plot the number of treated units at a given time period beneath the corresponding
ATT estimate.
The dynamic treatment effects plot displays the temporal heterogeneity of treatment
effects in an intuitive way. It is also a powerful visual tool for researchers to evaluate how
plausible the identifying assumptions are. Next, we introduce several statistical procedures
that formally test the implications of these assumptions. We start with a placebo test.
3.2. A Placebo Test
The basic idea for the placebo test is straightforward: we assume that the treatment starts
S periods earlier than its actual onset for each unit in the treatment group T and apply
the same counterfactual estimator to obtain estimates of ATTs for s = −(S − 1), . . . ,−1, 0.
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We can also estimate the overall ATT for the S pretreatment periods. If Assumptions 1-3
hold, we should expect the magnitude of this fake “ATT” estimate is close to zero. If this
“ATT” estimate is statistically different from zero, we obtain a piece of evidence that some
or all of the identifying assumptions are likely to be invalid.5 For example, a feedback effect
from past outcome to current treatment exists (e.g., Yt−1 and Dt are positively correlated in
Figure 1), which is a failure of the strict exogeneity assumption, it is likely to be detected
by the placebo test given sufficient data.
Because a placebo test is a test for equivalence, as Hartman and Hidalgo (2018) point
out, a simple difference-in-means approach may suffer from limited power; that is, when the
number of observations is small, failing to reject the null of the zero placebo effect does not
mean equivalence holds. To address this concern, we introduce a variant of the equivalence
test, where the null hypothesis is reversed:6
ATT p < −θ2 or ATT p > θ1,
in which −θ2 < 0 < θ1 are prespecified parameters, or equivalence thresholds. Rejection of
the null hypothesis implies the opposite holds with a high probability, i.e., −θ2 ≤ ATT p ≤ θ1.
In other words, if we collect sufficient data and show that the fake “ATT” falls within
a prespecified narrow range, we obtain a piece of evidence to support the validity of the
identifying assumptions. [−θ2, θ1] is therefore called the equivalence range. We use the two
one-sided tests (TOST) to check the equivalence of ATT p to zero. Following Hartman and
Hidalgo (2018), we set θ1 = θ2 = 0.36σ̂ε, in which σ̂ε is the standard deviation of the
residualized untreated outcome;7 alternatively, researchers may set the equivalence range
5In practice, S should not be set too large because the larger S is, the fewer pretreatment
periods will remain for estimating the model. If both S and Ntr are too small, however, the
test may be underpowered. In this and the following examples, we set S = 3.
6Egami and Yamauchi (2020) propose a similar test in a multi-period DiD setup.
7Specifically, we run a twoway fixed effects model with time-varying covariates using un-
treated data only and calculate the standard deviation of the residuals. The literature maps
18
based on an effect size they deem reasonable.
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Note: The above figure shows the results of the placebo tests based on three different estimators: FEct,
IFEct, and MC. The bar plot at the bottom of each panel illustrates the number of treated units at the
given time period relative to the onset of the treatment. The red dashed lines indicate the true ATT. Three
pretreatment periods (s = −2,−1, 0) serving as the placebo are rendered in blue. The p-values for the t test
of the placebo effect and for the TOST are shown at the top-left corner of each panel. The equivalence range
is set as [−0.36σ̂ε, 0.36σ̂ε].
One advantage of the placebo test is that it is robust to model misspecification and
immune from over-fitting because it relies on out-of-sample predictions of Y (0) in the placebo
periods. In this example, we use the true ATT to set the equivalence range. Figure 5 shows
the results from the placebo tests based on the three counterfactual estimators. We see
that for FEct and MC, we can reject the null that the placebo effect is zero under the
DiM test but cannot reject the null that the effect is outside the equivalence range—hence,
equivalence does not hold—while IFEct behaves in the exact opposite way: the placebo effect
is statistically indistinguishable from zero (p = 0.534), and we can reject the null hypothesis
that the placebo effect is bigger than the true ATT (p = 0.000). Although the MC method
fits the pretreatment periods well, it does not pass the placebo test using either the DiM
approach (p = 0.000) or the equivalence approach (p = 0.131).
The main shortcoming of the equivalence approach is that researchers need to prespecify
the equivalence range. [0.36σ̂ε, 0.36σ̂ε] may be too lenient when the effect size is small
it at a moderate effect size.
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relative to the variance of the residualized outcome. An alternative the literature suggests
is to benchmark the minimum range against a reasonable guess of the effect size based
on previous studies (e.g., Wiens 2001). However, such information is often unavailable.
Because the ATT estimates from a TSCS analysis can be severely biased due to failures of
the identification assumptions, unlike in experimental settings, they cannot provide valuable
information for the true effect size, either. Moreover, setting the equivalence range in a
post hoc fashion can lead to problematic results (Campbell and Gustafson 2018). The best
practice would be for researchers to preregister a plausible effect size and use it to set the
equivalence range before analyzing data, as is a common practice in clinical trials.
3.3. Two Extensions
We now extend the placebo test to testing (1) whether a pretrend exists, especially when
it takes place a few periods before the treatment starts; and (2) whether the treatment has
carryover effects.
A test for no pretrend. When a potential time-varying confounder is cyclical or does not
present itself right before the treatment’s onset, the placebo test may not be able to pick it
up. Under this circumstance, we need a more global test for no pretrend. A natural approach
is to jointly test a set of null hypotheses that the average of residuals for any pretreatment
period is zero, i.e., ATTs = 0 for all s ≤ 0 using an F test (see SI for details). However,
because the test for no pretrend is also a test for equivalence, we develop an equivalence test
with the following null:
ATTs < −θ2 or ATTs > θ1, ∀s ≤ 0,
in which [−θ2, θ1] is the equivalence range. In other words, the null is considered rejected
(hence, equivalence holds) only when the tests for all pretreatment periods generate sig-
nificant results. This is clearly a conservative standard, as we are simultaneously testing
multiple hypotheses; as a result, the Type-I error will be smaller than the test size (e.g.,
20
0.05).8 The equivalence approach has an additional advantage over the F test in that when
the sample size is large, a small confounder (or a few outliers) that only contributes to a
neglectable amount of bias in the causal estimates will almost always cause rejection of the
null hypothesis of joint zero means. The equivalence test avoids this problem.
Building upon the basic idea of the placebo test, we use a leave-one-period-out approach
to obtain an average out-of-sample prediction error for each period before the treatment’s
onset as long as data permits. Given a prespecified equivalence range, each of the TOST
rejects the null of inequivalence when the bootstrapped one-sided confidence interval of
pretreatment ATTs (average prediction error in period s) falls within the range. In addition,
we also calculate the minimum range, the smallest symmetric bound within which we can
reject the null of inequivalence using our sample. In other words, the minimal range is
determined by the largest absolute value of the range of the 90% confidence intervals of
ÂTT s,s≤0 in the pretreatment periods if we control the size α = 0.05. A rule of thumb is
that when the minimum range is within the equivalence range, the test is considered passed.
In SI, we compare the performance of the F test and the equivalence test using simulations.
Figure 6 demonstrates the results of the equivalence test based on FEct, IFEct, and MC using
the simulated dataset. With FEct, the trend leading towards the onset of the treatment goes
beyond the equivalence range and results in a wide minimum range. Therefore, we cannot
reject the null that the pretreatment average prediction errors are beyond a narrow range—
in other words, we cannot say that equivalence holds with high confidence. However, both
IFEct and MC pass the test. The 90% confidence intervals of the pretreatment prediction
error averages are within the equivalence range and the minimum range is narrower than the
8In SI, we present an alternative approach: an equivalence F test, which addresses the
multiple testing issue. However, its main drawback is that researchers cannot easily link the
equivalence range with a substantive effect size. Because the goal of an equivalence test is
to control the Type-I error, multiple testing, which makes the test more conservative, is not
a major concern. See Hartman (2020) (footnote 11) for a discussion.
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Figure 6. Tests for No Pretrend: The Simulated Example
F test p−value: 0.000
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Note: The above figure shows the results of the equivalence tests based on three different estimators:
FEct, IFEct, and MC. Pretreatment average prediction errors and their 90% confidence intervals are
drawn. The red dashed lines mark the equivalence range, while the gray dashed line marks the minimum
range. The bar plot at the bottom of each panel illustrates the number of treated units at the given
time period relative to the onset of the treatment.
equivalence range. Note that the F test p-value for MC is 0.000, which points to potential
model misspecification.
A test for no carryover effects. We extend the idea of the placebo test to testing the
presence of carryover effects. Instead of hiding a few periods right before the treatment starts,
we hide a few periods right after the treatment ends and predict Yit(0) in those periods. If
carryover effects do not exist, we would expect the average prediction error in those periods
to be close to zero. Once again, we use both the DiM approach and the equivalence approach.
Figure 12 shows the results from applying this test to the simulated sample. Different from
the dynamic treatment effects plot, the x-axis is now realigned based on the timing of the
treatment’s exit, not onset, e.g., 1 represents one period after the treatment ends. The
results show that the carryover effect does not seem to exist no matter which estimator or
test is used, which is consistent with the DGP.
It is worth noting that the failure of the no carryover effects assumption does not ne-
cessarily invalidate our counterfactual estimation approach. If, by employing the proposed
test, researchers find that the treatment effect persists after the treatment ends but in a
limited time window, one strategy to proceed is to leave a sufficient number of periods after
22
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Note: The above figure shows the results of the tests for no carryover effects based on three different
estimators: FEct, IFEct, and MC. The bar plot at the bottom of each panel illustrates the number of
treated units at the given time period relative to the onset of the treatment. The red dashed lines indicate
the true ATT. Three pretreatment periods (s = 1, 2, 3) after the treatment ends are rendered in pink. The
p-values for the t test of the carryover effect and for the TOST are shown at the top-left corner of each panel.
The equivalence range is set as [-eff, eff], in which eff is the true ATT.
the end of the treatment as “treated” and estimate the effects over these periods (as we
do in the proposed test). Alternatively, researchers can change the definition of the treat-
ment to “Dit = 1 if a units has ever been under the treatment conditions, and otherwise,
Dit = 0,” which essentially converts treatment assignment to a staggered adoption process,
thus making the assumption for the no carryover effects unnecessary.
We summarize the diagnostic tests in Table 1. To lend support to the identifying as-
sumptions, researchers can use either the DiM approach, if power is not a big concern, or the
equivalence approach, if they have prior knowledge about the approximate effect size. No
matter which approach researchers choose to use, visual inspection is always the first line of
defense against erroneous causal claims based on invalid identifying assumptions.
4. Empirical Examples
We now apply the counterfactual estimators, as well as the diagnostics tools, to two empir-
ical examples in political economy. The first example has a staggered adoption treatment
structure while in the second one, the treatment, switches back and forth. We start with
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Table 1. Diagnostic Tests Summary
Placebo test Testing (no) pretrend Testing (no) carryover effects
t test TOST F test TOST t test TOST
Null ATT p = 0 |ATT p| > θ ATTs = 0,∀s ≤ 0 |ATTs| > θ,∃s ≤ 0 ACOE = 0 |ACOE| > θ












Equivalence threshold θ 0.36σ̂ε or eff 0.36σ̂ε or eff 0.36σ̂ε or eff
Note: Both the t and F tests are conventional difference-in-means tests, testing against the null of no
difference. “Assumptions” refers to Assumptions 1-3 as a whole. σ̂ε is the standard deviation of the residuals
after twoway fixed effects are partialled out using untreated data only. ATT p denotes the average placebo
treatment effect on the treated. ACOE denotes the average carryover effect. “eff” represents an effect size
that researchers deem reasonable.
FEct. If the results from FEct pass both the “eyeball” test and the diagnostic tests, there is
little need for more complex methods except for potential efficiency gains. If, however, the
visual inspection or the tests suggest the identifying assumptions are unlikely to be true, we
apply IFEct and MC and run diagnostics again. In both applications, we set S = 3 in the
placebo tests. All uncertainty estimates are obtained using clustered bootstrap at the unit
level 1,000 times.
Direct democracy and naturalization rates. Hainmueller and Hangartner (2015) study
whether switching from direct democracy to indirect democracy increases naturalization rates
for minority immigrants in Swiss municipalities using a generalized DiD design. The outcome
variable is minorities’ naturalization rate in municipality i during year t. The treatment is
a dummy variable indicating whether naturalization decisions are made by popular referen-
dums. The dataset consists of 1,211 Swiss municipalities over 19 years, from 1991 to 2009.
The authors report that the naturalization rate increases by 1.339 percent on average (with
a standard error of 0.161) after a municipality shifts the decision-making power from popular
referendums to elected officials using a twoway fixed effects model.
We then apply FEct and obtain an estimate of 1.767 (with a standard error of 0.197), even
larger than the original estimate. Plots for the dynamic treatment effects and placebo test
are shown in Figure 8. We find that, first, the residual averages in the pretreatment periods
are almost flat and around zero and the effect gradually takes off after the treatment begins.
24







−15 −10 −5 0 5





















































−15 −10 −5 0 5






























F test p−value: 0.022






















(c) Testing No pretrend
Note: The above figure shows the results from applying FEct to data from Hainmueller and Hangartner
(2015), who investigate the effect of decisions made by municipal councilors (vs. popular referendums) on
naturalization rates of immigrant minorities in Swiss municipalities. The left panel shows the estimated
dynamic treatment effects using FEct. The middle panel shows the results from a placebo test using the
“treatment” in three pretreatment periods as a placebo. The right panel shows the results of an equivalence
test for no pretrend, in which the red and gray dashed lines mark the equivalence range and the minimum
range, respectively. The bar plot at the bottom of each panel illustrates the number of treated units at a
given time period relative to the onset of the treatment.
Second, with the placebo test, we cannot reject the null of zero placebo effect (p = 0.425),
while we can reject the null whose magnitude is bigger than the default equivalence threshold
(p = 0.000). Third, although the FEct estimator does not pass the F test at the 5% level
(p = 0.022), it passes the TOST (p = 0.001). The test for carryover effects is not applicable
because of the staggered adoption treatment structure. We also apply both IFEct and MC
estimators to this example. It turns out that the cross-validation schemes find zero factors, in
the case of IFEct, and a tuning parameter bigger than the first singular value of the residual
matrix, in the case of MC, both of which imply maximum regularization (no factors). Hence,
both methods reduce to FEct and give the exact same estimates as FEct.
In short, results from FEct are substantively the same as those from conventional twoway
FE models. However, counterfactual estimators like FEct allow us to check the validity of
the identifying assumptions in a more convenient and transparent way.
Partisan alignment and grant allocation. Our second example is based on Fouirnaies
and Mutlu-Eren (2015), in which the authors investigate whether partisan alignment between
25
local councils in England and the central government bring localities more grants. The
outcome of interest is the logarithm of specific grants per capita allocated to a local council.
The treatment is a dummy variable indicating whether the government party controls the
majority of local councils. The dataset spans 466 local councils from 1992 to 2012. The
authors add locality-specific linear time-trends to a twoway FE specification and find that
partisan alignment increases specific grants allocated to a council—the increase peaks three
years after alignment (see Figure A9 in SI for the original figure). A twoway FE model
without the locality-specific trends, however, returns negative estimates for the effect of
partisan alignment.
We apply the three estimators to the data and plot the estimated dynamic treatment
effects in Figure 9(a). It shows that, with FEct, the pretreatment residual averages con-
sistently deviate from zero, suggesting potential violations of the identifying assumptions.
With IFEct and MC, however, these estimates are very close to zero. Figure 9(b) shows
the results from the placebo test. With FEct, we cannot reject the null hypothesis of a
non-zero placebo effect at the 5% level. With either IFEct or MC, both the DiM (t test)
and the equivalence tests suggest the placebo effect is close to zero; however, IFEct seem to
approximate the data better than MC as the pretrend looks almost completely flat and the
estimated treatment effects are close to those in Figure 9(a).9 Finally, we report the results
from the test for carryover effects in Figure 9(c), in which we test the carryover effects up to
five years after partisan alignment ends. Based on the result from IFEct, the test suggests
that there are positive carryover effects at least three years after partisan alignment ends.
As discussed earlier, violation of the no carryover effect assumption does not necessarily
invalidate the research design, but suggests that a more flexible estimation strategy (like
ours) is required. Combining these three types of plots, we now have a full picture of how
partisan alignment may have affected specific grant allocation in England during this period.
We provide additional information on this empirical example in SI.
9The results from the equivalence tests are not greatly informative and are reported in SI.
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(c) Test for Carryover Effects
Note: The above figure shows the results from applying the counterfactual estimators, as well as diagnostic
tests, to data from Fouirnaies and Mutlu-Eren (2015). The bar plot at the bottom of each panel illustrates




Although the commonly used twoway FE models require strong assumptions to produce
interpretable causal estimates, they remain highly valuable because of their versatility in
accommodating different data structures and their high computational efficiency. In this
paper, we seek to improve current practices with FE models by providing a simple but
powerful counterfactual estimation framework, the key to which is to fit data in the controls
and impute counterfactuals to the treated, and by offering easy-to-implement diagnostic tests
to assist researchers in probing the validity of the identifying assumptions.
We discuss three estimators under this framework, including FEct, IFEct, and MC.
Table 2 compares these estimators and other existing approaches and shows that they have
several important advantages: they address the negative weighting problem, accommodate
general panel treatment structure without discarding data, can flexibly incorporate time-
varying covariates, and are amenable for diagnostic tests. In addition, IFEct and MC can
account for decomposable time-varying confounders.
Table 2. Comparison of Methods
DiD wDID DiDM FE w2FE FEct IFEct/MC
Accommodate heterogeneous treatment effects x x x x x x
Allow treatment reversal x x x x x
Condition on time-invariant covariates x
Condition on time-varying covariates x x x
Use most available data x x x x x
Easy-to-implement diagnostic tests x x x x
Condition on Uit = λ
′
ift x
Note: wDID, DiDM , 2FE, w2FE represent weighted DiD (Strezhnev 2018; Callaway and Sant’Anna 2020),
DiD multiple (de Chaisemartin and d’Haultfoeuille 2020), twoway FE, weighted twoway FE (Imai and Kim
2021), respectively. Uit = λ
′
ift represents decomposable time-varying confounders.
Importantly, we improve the existing practice of estimating and plotting dynamic treat-
ment effects and develop several statistical tests based on the new plot. These tests are based
on out-of-sample predictions of untreated potential outcomes, and thus are immune to model
misspecification or overfitting. We recommend researchers use the visual and statistical tests
in a holistic manner to gauge the validity of the identifying assumptions, as we do with two
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empirical examples. Below we provide a checklist as a practical guide to analyzing TSCS
data using counterfactual estimators:
• Plot the treatment status of your data and ask whether strict exogeneity assumption is
a plausible description of the treatment assignment process in your data; if not, consider
using methods based on sequential ignorability.
• Plot the outcome variable in a time-series fashion to spot outliers and irregularities; trans-
form the data if necessary.
• Start with the simplest estimator, FEct, draw the dynamic treatment effects plot and
perform both visual inspection and diagnostic tests (using either the DiM approach or the
equivalance approach).
• If the results for FEct imply invalid assumptions, apply more complex models, such as
IFEct and MC, and perform diagnostics again.
• Optionally, if a treatment effect is detected, perform subgroup analysis to understand
which group(s) of units are driving the effect.
• Communicate your findings effectively (ideally with figures).
Our methods have several limitations. First, the strict exogeneity assumption, which
corresponds to within-unit randomization, may be unrealistic in many applied settings, in
which case researchers should consider methods based on sequential ignorability (Blackwell
and Glynn 2018; Imai, Kim and Wang 2018; Hazlett and Xu 2018). Second, although
we provide flexible modeling options, such as IFEct and MC, they are no panacea for all
TSCS applications. The factor-augmented approach is more likely to suffer from biases
due to model dependency and misspecification. Researchers have recently made efforts to
alleviate this concern by proposing doubly robust estimators (e.g., Ben-Michael, Feller and
Rothstein 2021; Arkhangelsky et al. 2019). We do not incorporate these innovations in this
paper because doing so would limit the applicability of our methods (e.g., by not allowing
treatment reversal). Last but not least, the equivalence test approach requires users to
29
specify an equivalence range, which may leave room for post hoc justification. Despite these
drawbacks, we believe that a counterfactual imputation approach is a promising framework
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6.1. Algorithms and Tests
6.1.1. The IFEct Algorithm
The IFEct algorithm takes for the following four steps.




















t for the untreated (Dit = 0):
Step 2a. Update β̂(h+1) using the untreated data only (we can set λ̂
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i = 0, f̂
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is fixed and does not need to be updated every time.
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For all untreated observations (i.e., Dit = 0) , calculate W
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it . For all treated observations
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.. . With restrictions:
∑N
i=1 αi = 0,∑T
t=1 ξt = 0,
∑N
i=1 λi = 0 and
∑T
t=1 ft = 0.
Step 2d. Update estimates of factors and factor loadings by minimizing the least squares
objective function using the complete data of W(h+1) = [W̃
(h+1)
it ]∀i,t:




(W(h+1) − F̃Λ̃′)′(W(h+1) − F̃Λ̃′)
]
s.t. F̃′F̃/T = Ir, Λ̃
′Λ̃ = diagonal
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Step 2e. Update estimates of grand mean and twoway fixed effects:













Step 3. Estimate treated counterfactual, obtaining:
Ŷit(0) = X
′
itβ̂ + α̂i + ξ̂t + λ̂
′
if̂t, for all i, t, Dit = 1
Step 4. Obtain the ATT and ATTs as in FEct.
6.1.2. The MC Algorithm
We summarize the algorithm for the matrix completion (MC) method below. First, define PO(A)
and P⊥O (A) for any matrix A:
PO(A) =

Ait, if(i, t) ∈ O.
0, if(i, t) /∈ O.
and P⊥O (A) =

0, if(i, t) ∈ O.
Ait, if(i, t) /∈ O.
Conduct Singular Value Decomposition (SVD) on matrix A and obtain A = SΣRT. The matrix
shrinkage operator is defined as shrinkθ(A) = SΣ̃R
T, where Σ̃ equals to Σ with the i-th singular
value σi(A) replaced by max(σi(A) − θ, 0), which is called “soft impute” in the machine learning
literature. The MC algorithm takes the following iterative steps:
Step 0. Given a tuning parameter θ, we start with the initial value L0(θ) = PO(Y).







Step 2. Repeat Step 1 until the sequence {Lh(θ)}h≥0 converges.
Step 3. Given Ŷit(0) = L̂
∗
it, and δ̂it = Yit − Ŷit(0), compute ATT and ATTs as before.
If we replace σi(A) by σi(A)1{σi(A) ≥ θ}, which is called “hard impute,” the algorithm will produce
estimates almost identical to the IFEct algorithm.
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6.1.3. The Difference-in-Means Tests and Equivalence Tests
The equivalence test we introduce in the main text takes the form of two one-sided tests (TOST) for
each pretreatment period s. We declare equivalence only when the test rejects the null hypothesis
in all the periods of interest. Figure 10 is adapted from Hartman and Hidalgo (2018) and shows
the difference between the usual t test and the TOST. The null hypothesis is rejected when the
test statistic’s value falls in the shaded region on both panels. But only the shaded region on the
right reflects the magnitude of Type-I error that we are trying to control for.
Figure 10. t distribution under the Two Tests
An alternative approach is an equivalence F test, which uses the same statistic as the F test:
F =
Ntr(Ntr −m− 1)
(Ntr − 1)(m+ 1)
δ′(−m:0)Σδ(−m:0)δ(−m:0)
where δ(−m:0) = (ATT−m, ATT−(m−1), . . . , ATT0)
′ and Σδ(−m:0) is the covariance matrix of δ(−m:0).




Wellek (2010) shows that under this hypothesis, the statistic converges to a non-central F -distribution
F (m + 1, Ntr −m − 1, Ntrκ2), where Ntrκ2 is the distribution’s centrality parameter. The null is
considered rejected (hence, equivalence holds) when the statistic’s value is smaller than the 100αth
percentile of the distribution. When the absolute values of all the ATTs are smaller, there will be a
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higher chance to reject the null . Based on the discussion in Wellek (2010) and simulation results,
we recommend to set κ = 0.6.
We compare the distribution of the F test with that of the equivalence test in Figure 11 above.
The solid black curve represents the distribution of the test statistic under the null of the F test.
The dotted black curve represents its distribution under the null of the equivalence test. We reject
the null under the former if the value of the test statistic falls on the right side of the solid red
line and reject the null under the latter if it falls on the left side of the dotted red line, i.e., the
equivalence threshold.
In the above case (with a chosen equivalence threshold of 0.6), the equivalence test is more
lenient than the F test: when the test statistic falls between the two red lines, we reject the null
under the F test (suggesting inequivalence), but also reject the null under the equivalence test
(declaring equivalence). Therefore, the equivalence test has the same advantages as the TOST
does. However, because its threshold is less intuitive and harder to interpret, we choose the TOST
as the primary approach to conduct the equivalence test.
Figure 11. F distribution under the Two Tests



















α (Equivalence F test)
Note: The above figure plots the distribution of the test statistic under the null of the F
test and its distribution under the null of the equivalence test. The shaded areas represent
the size of the two tests (α = 0.05).
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6.1.4. Discussion on the No Carryover Effects Assumption
The violation of no carryover effects assumption is a violation of the stable unit treatment value
assumption (SUTVA) along the temporal dimension, i.e., the potential outcome of unit i in period
t could be affected by its own treatment status in earlier periods. Therefore, the presence of
carryover effects is equivalent to temporal interference and does not imply failure of the strict
exogeneity assumption.
As we briefly discuss in the main text, violations of the no carryover effects assumption is not
a concern under staggered adoption; it is a concern when the treatment switches on and off for
some unit. In the latter case, the carryover effects can be seen as a result of special “time-varying
confounders.” Hence, we can use the placebo test introduced earlier in paper to gauge whether
they exist. When the average prediction error in those periods deviate from zero, we obtain a piece
of evidence that the assumption is likely invalid (of course, it is also possible it is a result of some
temporal shocks unrelated to carryover effects). A potential solution in this scenario is to re-code
the treatment such that we label a few periods after the treatment’s ending as under treatment to
allow the carryover effects to fully present themselves.

























Instant Effect from Dt
Carryover Effect from Dt−1
Carryover Effect from Dt−2
Carryover Effect from Dt−3
Carryover Effect from Dt−4
Note: The above figures demonstrates a decomposition of δit in a hypothetical case under staggered adoption
when carry over effects exist. The x-axis indicates the time relative the onset of the treatment.
Under staggered adoption, however, we may not be concerned about the carryover effect because
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we can reinterpret δit as a combination of the instant effect of the current treatment (red area in
Figure 12) and cumulative carryover effects of past treatments (other colored areas) on a treated
unit i relative to its potential outcome history under the never-treated condition.
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6.2. Proofs
6.2.1. Unbiasedness and Consistency of FEct and IFEct
Denote the number of all observations, the number of observations with Dit = 1, and the number
of observations with Dit = 0 as n, nM, and nO, respectively. Under FEct, our Assumptions 1, 2,
and 3 lead to the following model specification:
Yit = X
′






εit ⊥ {Djs,Xjs, αj , ξs} for any i, j ∈ {1, 2, . . . , N} and s, t ∈ {1, 2, . . . , T}.
The data we use to estimate these parameters constitute an unbalanced panel since we are not
using observations whose Dit = 1. Following Wansbeek and Kapteyn (1989), we rearrange the
observations so that data on N units “are ordered in T consecutive sets”, thus the index t “runs
slowly” and i “runs quickly.” Denote the number of untreated units in period t as Nt, then Nt ≤ N
and
∑T
t=1Nt = nO, the number of untreated observations in the dataset. Similarly, denote the
number of periods in which unit i is untreated as Ti. Then Ti ≤ T and
∑N
i=1 Ti = nO. Let Mt
be the Nt × N matrix where row i equals to the corresponding row in the unit matrix IN if i is
observed in period t. Then we can rewrite Equation (1) in the matrix form:
Y = Xβ + ∆(α, ξ)′ + ε
where X = (x11,x21, · · · ,xNT )′ is a nO ×K matrix, ιn denotes the nO-dimension vector consisted




























′Λ = diagnal,F′F/T = Ir,
εit ⊥ {Djs,Xjs, αj , ξs, λj , fs} for any i, j ∈ {1, 2, . . . , N} and s, t ∈ {1, 2, . . . , T}.
in which Λ = [λ1, λ2, . . . , λN ]
′ and F = [f1, f2, . . . , fT ]
′. From now on we denote the projection
matrix of matrix A as PA and the corresponding residual-making matrix as QA.
Proving the ATT estimator’s consistency requires some regularity conditions. First, following
Bai (2009) and Xu (2017), we assume that the error terms have weak serial dependence:
Weak serial dependence:
1. E [εitεis] = σi,ts, |σi,ts| ≤ σ̄i for all (t, s) such that 1N
∑N
i σ̄i < M .


















i,j,k,l |cov [εitεjt, εksεls] | ≤M .
4. E [εitεjs] = 0 for all i 6= j, (t, s).
These assumptions imply Assumption 3 in Moon and Weidner (2017) that ||ε||NT → 0 as N,T go to
infinity. We also need some restrictions on parameters in the models:
Restriction on parameters:
1. For each t, NtN → pt as N →∞, where 0 ≤ pt < 1 is a constant that varies with t.
2. All entries of the matrix E [xitxit
′] is bounded by M .




t Xit,k ≤ M for
any (k, j).







}K×K and w(λ) as the smallest eigenvalue of W (λ). Define







}K×K and w(f) as the smallest eigenvalue of W (f). Then either
limN,T→∞minλ w(λ) > 0, or limN,T→∞minf w(f) > 0 holds.
The last restriction comes from Moon and Weidner (2017) for the consistency of the IFEct
model.
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Lemma 1 Under model specification (A1) and regularity conditions, all the following limits10 exist:
(a) limN→∞
X′X
N , (b) limN→∞
X′ε
N , (c) limN→∞
X′∆2
N , (d) limN→∞
∆′2∆2







N , where diag{
1
Ti
} is a diagonal matrix with 1Ti being the ith entry on
the diagonal.
Proof: We start from proving (a). When the regularities conditions are satisfied, we can apply the



































































where Ai is a K × T matrix, and the tth column of Ai equals to 0K×1 when Dit = 1 and equals to
xit when Dit = 0. Clearly the limit exists under regularity conditions.




























t Xit,k. It is bounded by
M
Ti
. (g) can be similarly proven.
Lemma 2 Under model specification (A1) and regularity conditions, a. estimates of β, αi, and
ξt from equations (1) to (3), i.e. β̂, α̂i, and ξ̂t, are unbiased, and b. β̂ and ξ̂t are consistent as
N →∞.
10All the convergences here are convergence in probability.
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Proof: As shown in Wansbeek and Kapteyn (1989), β under model specification (A1) can still be
estimated using the within estimator. Multiplying both sides of demeaned equation (4) with Q[∆],




−1X′Q[∆][Xβ + ∆(α, ξ)
′ + ε]
= β + (X′Q[∆]X)
−1X ′Q[∆]ε
Hence, E[β̂] = β + E[(X′Q[∆]X)
−1X′Q[∆]ε] = β, and E[µ̂] = E[Ȳ − X̄β̂] = Ȳ − X̄β = µ.
Similarly,
Q[X]Y = Q[X]∆(α, ξ)
′ +Q[X]ε
The level of fixed effects, (α, ξ)′, can also be estimated using ordinary least squares under the two
constrains (2) and (3), which is equivalent to the following constrained minimization problem:
Minγ (Q[X]Y −Q[X]∆γ)′(Q[X]Y −Q[X]∆γ)
with Πγ = 0
where γ = (α, ξ)′, and Π1×(N+T ) =
(
T1, T2, . . . , TN ,−N1,−N2, . . . ,−NT
)
.














where λ represents the corresponding Lagrangian multipliers. Finally, γ̂ = (α̂, ξ̂)′ = Φ−111 ∆
′Q[X]Y .
Here Φ−111 is the upper-left block of Φ
−1. For unbiasedness of these estimates, notice that





= E[(I − Φ−112 Π)(α, ξ)
′]
= (α, ξ)′.








12 Π = I. The last equality exploits the constraint Π(α, ξ)
′ = 0.
41












































































Using Lemma 1, we know that as N → ∞, each term in the expression above will converge in

















 converges to 0N×1 as N →∞,
which leads to the consistency result.
On the contrary, α̂i is inconsistent when only N → ∞ as the number of parameters changes
accordingly.
Lemma 3 Under model specification (A2) and regularity conditions, a. estimates of β, αi, ξt, λi,
and ft from equations (5) to (9), i.e. β̂, α̂i, ξ̂t, λ̂i, and f̂t are a. unbiased, and b. consistent as
N,T →∞.
Proof: Moon and Weidner (2017) show that all the coefficients of an IFE model can be estimated
via a quasi maximum likelihood estimator and the estimates are unbiased as well as consistent when
both N and T increase to infinity. We also know that estimates obtained from the EM algorithm
converge to the quasi-MLE solution since it is the unique extrema. Hence the lemma holds due to
properties of QMLE.
Proposition 1 (Unbiasedness and Consistency of FEct) : Under model specification (A1),
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as well as regularity conditions,
E[ÂTT s] = ATTs; E[ÂTT ] = ATT ;
ÂTT s −ATTs
p→ 0; and ÂTT −ATT p→ 0 as N →∞.
















X′it(β − β̂) + (αi − α̂i) + (ξt − ξ̂t) + δit
}


































(δit + αi − α̂i) + X̄ ′it(β − β̂) + (ξt − ξ̂t)
Lemma 2 indicates that as N → ∞, β̂ and ξ̂t converge to β, and ξt, respectively. The only





(αi − α̂i) = 0. This is true since E [αi − α̂i] = 0 and
Var [αi − α̂i] is bounded by the regularity conditions. Therefore limN→∞(ÂTTs− 1|S|
∑
(i,t)∈S δit) =
limN→∞(ÂTTs −ATTs) = 0, consistency holds.
Proposition 2 (Unbiasedness and Consistency of IFEct) : Under model specification (A2),
as well as regularity conditions,
E[ÂTT s] = ATTs and E[ÂTT ] = ATT ;
ÂTT s
p→ ATTs and ÂTT
p→ ATT as N,T →∞.
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Proof: From lemma 3, we know that estimates for β, αi, ξt, λi, and ft are unbiased and consistent
as N,T →∞. Hence, ÂTTt and ÂTT are also unbiased and consistent, following the same logic in
the proof of Proposition 1.
6.2.2. FEct as a Weighting Estimator
Proposition 3 (FEct as a weighting estimator) : Under model specification (A1), and when
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(j,s)∈O





















Proof: When there is no covariate,
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Note that under the constraints, the fixed effects are independent to each other. Hence, for the















js = 0, as on the left-hand side there are only α̂i and ξ̂t. We can see that the
weight for each untreated observation (j, s) is larger if there are fewer untreated observations in
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unit j or period s.
We now use a simple example to compare weights under the FEct estimator and those under
the classic FE estimator. Consider a dataset with 3 units and 4 periods and the treatment status
is as follows:
Table 3. Treatment Status
Periods
1 2 3 4 D̄i.
1 0 0 0 0 0
Units 2 0 0 0 1 1/4
3 0 1 1 1 3/4
D̄.t 0 1/3 1/3 2/3 5/6
where D̄i. is the average treatment status of unit i and D̄.t is the average treatment status
of period t. We have 4 treated observations, (2, 4), (3, 2), (3, 3), and (3, 4), and 12 untreated








10 δ̂34, where each wit =
εit∑
it:(i,t)∈M εit
and εit = Dit − D̄i. − D̄.t + D̄. The
last estimate contributes negatively to the ATT estimate. Meanwhile, the FEct estimator, δ̂FEct,






4 δ̂34. All the four weights are equal and positive. Under both FE
and FEct, δ̂it = W
(it)′YO, where the weights satisfy constraints in Proposition 3 (and conditions




We rely on nonparametric block bootstrap and jackknife—both clustered at the unit level—to
obtain uncertainty estimates for the treatment effect estimates. In the bootstrap procedure, we
resample, with replacement, an equal number of units from the original sample. When a unit is
drawn, its entire time series of data, including the outcomes, treatment status, and covariates, are
replicated. We obtain standard errors and confidence intervals of treatment effect estimates using
conventional standard deviation and percentiles methods, respectively (Efron and Tibshirani 1993).
When the number of treated units is small (but bigger than one), jackknife resampling is an
appealing alternative to bootstrapping (Miller 1974; Efron and Stein 1981). In each run, the
procedure drops one unit (again, with its entire time series) and re-estimates the treatment effects.




− ÂTT )2, in
which ÂTT
−i
is the ATT estimate from the sample in which the i’th unit is dropped and ÂTT is
the average of jackknife estimates. We obtain confidence internals and p-values using a standard
normal distribution. To address Bertrand, Duflo and Mullainathan (2004)’s well-known critique,
both methods allow the error terms to be serially correlated but assume homoscedasticity of the
errors across units. Both methods require the number of units N to be large.
We study the finite sample properties of the bootstrap and jackknife variance estimators using
simulations. We simulate samples with T = 20 and N = 30, 50, 100 and a staggered adoption
treatment assignment mechanism. We assume that no time-varying confounders exist while the
treatment effects are heterogeneous, hence, FEct is consistent for the ATT while the twoway fixed
effects model is not. Following Arkhangelsky et al. (2019), we plot the quantiles of the distribution
for standardized errors of the ATT estimates, i.e., (ÂTT − ATT )/V̂ar(ÂTT )1/2, based on 1,000
simulated samples against the quantiles of the standard normal distribution—a Quantile-Quantile
plot (QQ plot)—using three combinations of estimators and inferential methods: (1) twoway fixed
effects with block bootstrapped standard errors; (2) FEct with block bootstrapped standard errors;
and (3) FEct with jackknife standard errors. If the ATT estimator is consistent and asymptotically
normal and the chosen variance estimator precisely estimates its variance, the QQ plot should be
very close to 45-degree line.
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(c) N = 100
Note: The above figures show the standard Gaussian QQ plot of the standardize errors (ÂTT −
ATT )/(V̂ar(ÂTT ))1/2 for the following combination of estimators and inferential methods: (1) twoway
fixed effects with block bootstrapped standard errors; (2) FEct with block bootstrapped standard
errors; and (3) FEct with jackknife standard errors, each aggregated from 1,000 simulations using
samples with dimensions T = 20 and N = 30, N = 50 or N = 100. The 45-degree indicates the
benchmark: consistent point estimates with perfectly calibrated Gaussian standard errors.
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Figure 13 presents the results. First, because the twoway fixed effects estimator is inconsistent,
the QQ plot does not pass point (0, 0). Second, when we apply the FEct estimator, both bootstrap
and jackknife procedures precisely estimate the variance of an ATT estimate: both QQ plots are
almost exactly on the 45-degree lines. Our finding suggests that the literature’s recommendation
to use block bootstrap or jackknife for variance estimation for panel models (Bertrand, Duflo and
Mullainathan 2004; Cameron and Miller 2015) can be extended to counterfactual estimators, such
as FEct, IFEct, and MC.
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6.4. Additional Monte Carlo Evidence
In this section, we report results of three sets of Monte Carlo exercises to demonstrate (1) the finite
sample properties of the proposed inferential methods; (2) the differences between the IFEct and
MC estimators, and (3) the main advantages of the equivalence test over the F test. Before doing
so, we first describe the data generating processes (DGP) of the simulated sample.
6.4.1. Describing the DGP of the Simulated Example
We describe the DGP of the simulated example as follows.
• Outcome model: Yit(0) = δitDit+5+1 ·Xit,1 +3 ·Xit,2 +1.5λi1 ·f1t+λi2 ·f2t+αi+ ξt+εit,
in which f1t is a linear trend plus a white noise: f1t = t + νt, and νt
i.i.d∼ N(0, 1), then it
is normalized to have variance 1. f2t is an i.i.d N(0, 1) white noise. Both λi1 and λi2 are
i.i.d N(0, 1). Two covariates X1,it and X2,it are included in the model. They are both i.i.d.
N(0, 1). Unit fixed effects αi ∼ N(0, 1). Time fixed effects ξt follows a stochastic drift. The
error term εit is also i.i.d. N(0, 2).
• Treatment effects: δit = 0.4st + eit, in which st represents the number of periods since the
latest treatment’s onset and eit is i.i.d. N(0, 0.2
2). This means the expected value of the
treatment effect gradually increases as a unit takes up the treatment, e.g. from 0.4 in the
first period after receiving the treatment to 2.0 in the fifth period.
• Treatment assignment: denote pit the probability of getting treated for unit i in period t:
logit(pit) = −1 + 0.5Dt−1 + 0.5λ′ift + 0.2αi + 0.2ξt + µit, in which µit
i.i.d∼ N(0, 0.12).
Note that this DGP satisfies Assumptions 1-3. Figures 14 and 15 show the treatment status and
outcome variable in the simulated example.
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Figure 14. Treatment Status: The Simulated Samples





Under Control Under Treatment
Treatment Status
Note: The above figure plots the treatment status of the simulated example, in which
treatment reversal is allowed. The plot is made by the panelView package.

















Note: The above figure plots the outcome variable in the simulated example. The plot is
made by the panelView package.
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6.4.2. IFEct versus MC
We compare the performance of the IFEct and MC estimators using DGPs similar to that of the




m=1 λim · fmt + αi + ξt + εit. We simulate samples of
200 units and 30 time periods, and all treated units receive the treatment at period 21 (T0 = 20).
Following Li (2018), we vary the number of factors r from 1 to 9 and adjust a scaling parameter
1√
r
such that the total contribution of all factors (and their loadings) to the variance of Y remains
constant. Our intuition is that IFEct (i.e., hard impute) performs better than MC (i.e., soft impute)
when only a small number of factors are present and each of them exhibits relatively strong signals
while MC outperforms IFEct when a large set of weak factors exist. In other words, MC should
handle sparsely distributed factors better than parametric models like IFEct.
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(c) Two-factor DGP: MC
Note: The above figures show the results from two Monte Carlo exercises that compare IFEct with
MC. Figure (a) compares the mean squared prediction errors (MSPEs) for treated counterfactuals using
the IFEct and MC estimators with different DGPs in which the total variance of all factors are kept
constant. Figures (b) and (c) compare the two estimators in terms of mean squared error (MSE) for
the ATT, biases and standard deviations (SD), as well as pretreatment root residual sums of squares
(sigma (Pre)) using different tuning parameters; the DGP is an IFE model with two factors.





[Y (0) − Ŷit(0)]2 , from 500 simulations using these two methods. The black
solid line and gray dashed line represent the MSPE of IFEct with the correct number of factors (r)
and with cross-validated r’s, respectively, while the red dot-dashed line marks the MSPEs of the
MC estimator with a crossed validated tuning parameter λ. The result shows that MC gradually
catches up with, and eventually beats, IFEct (with correctly specified r) as the number of factor
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grows and each factor produces weaker signals. It also suggests that, when factors become weaker,
it is more difficult for the cross-validation scheme to pick them up, resulting in worse predictive
performance, while the MC estimator is robust to a large number of factors because factors and
loadings are not directly estimated.
In Figure 16(b), we fix the DGP with two factors and compare the performances of IFEct
and MC with different tuning parameters. The black solid lines, gray long-dashed lines, gray
dot-dashed lines, and red long-dashed lines represent (1) the biases of the ATT estimates, i.e,
E(ÂTT − ATT ), (2) their standard deviations (SD), (3) their MSEs and (4) standard deviation
of residuals in the pretreatment periods—a measure of pretreatment model fitness—respectively.
We observe several patterns. First, as expected, with the most favorable tuning parameters, IFEct
outperforms MC in terms of both bias and variance because an MC model is mis-specified. Second,
as more factors are included in the IFEct model or the tuning parameter becomes smaller with
MC, both models start to over-fit: the model fits pretreatment data better and better while MSE
for the ATT deteriorates. These findings strongly suggest that the pretreatment model fitness is
poor indicator of model performance and a high level of model fitness in the pretreatment periods
does not necessarily lead to more precise estimates of the ATT.
6.4.3. F Test versus the Equivalence test.
As explained in the paper, we prefer the equivalence test to the F test for testing no pre-trend
for two reasons: (1) the former is more conservative than the latter in the presence of a large
confounder when the sample size is small; and (2) when the sample size is relatively large, the
former can tolerate confounders that only result in a small amount of bias in the causal estimates
while the latter cannot. To illustrate these, we simulate data using the following DGP similar to
that in the previous section but with only one factor: Yit = δitDit+5+k ·λift+αi+ξt+εit, in which
we vary k to adjust the influence of a potential confounder Uit = λift, which is correlated with Dit.
For each k, we run 600 simulations. In each simulation, we first generate a sample of N = 100 units
(50 treated and 50 controls) of 40 periods. We estimate a FEct model without taking into account
the time-varying confounder. We then expand the sample size such that N = 300 and re-do the
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analysis.
In Figure 17(a), we plot the proportion of times the equivalence test (solid line) or the F test
(dashed line) backs the strict exogeneity assumption against the normalized bias induced by the
confounder when N = 100. It shows that it is highly likely that an F test cannot reject the null of
zero residual average due to lack of power, even when the biases are large. In contrast, the prob-
ability that the equivalence test rejects inequivalence (hence, declaring equivalence) drops quickly
as the bias increases. In other words, the equivalence test is more powerful in detecting imbalances
than the conventional F test. Figure 17(b) shows that, when the sample size is relatively large
(N = 300), the non-rejection rate of the F test declines quickly as the influence of the confounder
grows. In comparison, the equivalence test rejects inequivalence (hence, declaring equivalence)
when a inconsequential confounder is at present; as the confounder becomes more influential (e.g.
causing a bias of 0.15 standard deviation of the residualized Y in the ATT), it starts to sound the
alarm. These patterns are similar to what Hartman and Hidalgo (2018) report in a cross-sectional
setting.
53
Figure 17. Monte Carlo Exercises: F vs. equivalence tests

















































Equivalence Test F Test
(a) N = 100
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(b) N = 300
Note: The above figures show the results from Monte Carlo exercises that compare the F test and the
equivalence test when an unobserved confounder exists. In plot (a), N = 100; in plot (b), N = 300. Each
dot is based on results from 600 simulations.
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6.5. Additional Information on the Empirical Examples
6.5.1. Replicating Hainmueller and Hangartner (2015)
Figure 18. Treatment Status: Indirect Democracy and
Naturalization Rate








Direct Democracy Indirect Democracy
Note: The above figure plots the treatment status for the first 50 units using data from
Hainmueller and Hangartner (2015). The pattern of treatment assignment follows staggered
adoption. Municipalities are ordered based on the timing when they started to adopt indirect
democracy to make naturalization decisions. The plot is made by the panelView package.
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6.5.2. Replicating Fouirnaies and Mutlu-Eren (2015)
Figure 19. Original Treatment Effect Plot
Note: The above figure is adapted from Fouirnaies and Mutlu-Eren (2015).
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Under Control Under Treatment Missing
Treatment Status
Note: The above figure plots the treatment status using data from Fouirnaies and Mutlu-Eren (2015). Local
councils in England are ordered based on the timing when they are politically aligned with the government
party. The plot is made by the panelView package.
Figure 21. The Effect of Partisan Alignment on Specific Grants
Testing No Pre-Trend
F test p−value: 0.000
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F test p−value: 0.953
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F test p−value: 0.003
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Note: The above figures show the results from tests for no pre-trend in the application of partisan alignment
on specific grants in the UK. The bar plot at the bottom of each figure illustrates the number of treated units
at a given time period relative to the onset of the treatment. Pretreatment residual averages and their 90%
confidence intervals are drawn; the red and gray dashed lines mark the equivalence range and the minimum
range, respectively. With the equivalence threshold set at 0.36σ̂2, all three models pass the equivalence test.
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g) Cohort: First Treated after 2010
(b) IFEct
Note: The above figures show the effect of partisan alignment on specific grants using FEct (a) and IFEct (b).
Cohorts are defined based on the timing when a local council in England is first aligned with the government
party. They broadly correspond to the three blocks of units in the treatment status plot (Figure 20).
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6.5.3. Replicating Xu and Yao (2015)
The following exercises show that it possible for an application to pass the placebo test, in which
only a few periods before the onset of the treatment is used for testing, but fail the the test for no
pre-trend, when many periods before the treatment starts are used for testing in a leave-one-out
fashion. Used together, the two tests are helpful in assisting researchers to gauge the validity of
the identifying assumptions.
Figure 23. Treatment Status: Clan Leaders and Public Investment






VC from a small Family VC from a Large Clan Missing
Note: The above figure plots the treatment status using data from Xu and Yao (2015).
Villages are ordered based on the timing when a candidate from large clans are elected
as the village chairperson. The plot is made by the panelView package.
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F test p−value: 0.462
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(c) Testing No Pre-Trend
Note: The above figures show the results from applying FEct to data from Xu and Yao (2015), who
investigate the effect of village chairpersons from large clans on the amount of public investment in Chinese
villages. The left figure shows the estimated dynamic treatment effects using FEct. The middle figure shows
the results from a placebo test using the “treatment” in three pretreatment periods as a placebo. The right
figure shows the results of an equivalence test for no pre-trend, in which the red and gray dashed lines
mark the equivalence range and the minimum range, respectively. The bar plot at the bottom of each figure
illustrates the number of treated units at a given time period relative to the onset of the treatment.
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